Prospective study of fatty acid synthetase (FAS) expression in breast cancer and progression of disease.
Fatty acid synthetase (FAS) mRNA was determined in breast carcinomas of 91 patients. The patients were followed for an average of 47 months. Disease-free survival and overall survival were compared with the expression of FAS-mRNA in the tumour. Sixty-five patients remained disease-free during the follow-up period; twenty-six had recurrent disease, and of those 18 died of the disease. Seventy-five percent of the tumours had low FAS-mRNA levels and there were fewer deaths in this group of patients (15%) than in that with high FAS-mRNA levels (35%). The proportion of recurrences was also smaller in the group with low FAS-mRNA. The probability of survival for five years was over 80% for the low FAS-mRNA group, and about 50% for the high FAS-mRNA group.